NCT00445692View on ClinicalTrials.gov

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 10, 2007

Primary Completion Date

April 24, 2017

Study Completion Date

April 24, 2017

Conditions
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Clarithromycin

Given Orally (PO)

DRUG

Dexamethasone

Given PO

DRUG

Lenalidomide

Given Orally (PO)

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00445692 - Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | Biotech Hunter | Biotech Hunter